Remdesivir

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

SARS-CoV2 Infection

Conditions

SARS-CoV2 Infection

Trial Timeline

— → —

NCT ID

NCT04323761

About Remdesivir

Remdesivir is a pre-clinical stage product being developed by Gilead Sciences for SARS-CoV2 Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04323761. Target conditions include SARS-CoV2 Infection.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04323761	Pre-clinical	Completed	—	—	SARS-CoV2 Infection
NCT06817889	Phase 2	Recruiting	Dec 23, 2025	Nov 30, 2027	Hematopoietic and Lymphatic System Neoplasm
NCT04582266	Pre-clinical	Completed	Mar 31, 2021	Apr 13, 2022	COVID-19
NCT04847622	Pre-clinical	Completed	Feb 12, 2021	Apr 30, 2021	Covid19
NCT04431453	Phase 2/3	Completed	Jul 21, 2020	Feb 10, 2023	COVID-19

Competing Products

3 competing products in SARS-CoV2 Infection

See all competitors

Product	Company	Stage	Hype Score
Tocilizumab 20 MG/ML	Roche	Phase 2	52
IMM-BCP-01 + Placebo	Immunome	Phase 1	28
VXA-CoV2-3.1 + COMIRNATY® + VXA-CoV2-3.3	Vaxart	Phase 2	44

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved